Weekly Digest - Jan 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Jan 2024
08 Jan 2024: At JPM24, Novartis CEO discusses resisting the ADC field trend among cancer players
- Novartis CEO reveals the company’s strategic choice of radioligand therapies over antibody-drug conjugates (ADCs) in cancer treatment
- Novartis focuses on expanding its radiotherapy portfolio, featuring PSMA-targeted Pluvicto and SSTR-aimed Lutathera, with plans to advance Pluvicto in earlier-stage prostate cancer treatment
- Despite being the only major cancer drug developer without an ADC deal, Novartis continues its innovative approach, acquiring capabilities through strategic partnerships and acquisitions in radiotherapy, cell and gene therapy, and RNA therapeutics
